Comment on "Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma: Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal"
Daly, Adrian
2022 • In Journal of Clinical Pharmacy and Therapeutics
Comment on 'Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal' Enhanced Reader.pdf
Daly, Adrian ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique
Language :
English
Title :
Comment on "Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma: Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal"
Yu N, Wang L, Yang H, Pan H, Duan L, Zhu H. Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal. J Clin Pharm Ther. 2022. doi:10.1111/JCPT.13615. Online ahead of print.
Chiloiro S, Giampietro A, Bianchi A, et al. Acromegaly can be cured by first-line pasireotide treatment? Endocrine. 2019;64:196-199. doi:10.1007/S12020-019-01874-4/FIGURES/3
Coopmans EC, Van MSWF, Pieterman KJ, et al. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019;181:K21-K27. doi:10.1530/EJE-19-0279
Yamamoto R, Shima KR, Igawa H, et al. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly. Endocr J. 2018;65:1061-1067. doi:10.1507/ENDOCRJ.EJ17-0487
Daly AF, Potorac I, Petrossians P, Beckers A. Shrinkage of pituitary adenomas with pasireotide. Lancet Diabetes Endocrinol. 2019;7:509. doi:10.1016/S2213-8587(19)30181-0
Raverot G, Vasiljevic A, Jouanneau E, Lasolle H. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. Eur J Endocrinol. 2019;181:C1-C3. doi:10.1530/EJE-19-0359
Daly A, Rostomyan L, Betea D, et al. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect. 2019;8:367-377. doi:10.1530/EC-19-0004
